ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Life Technologies has bought Pinpoint Genomics, maker of a polymerase-chain reaction-based assay for non-small-cell lung cancer. The Pinpoint Dx Lung Assay runs on Life Technologies’ qPCR platform. Life Technologies says it hopes to improve patient survival rates by bolstering use of the Pinpoint assay, which it claims is more accurate than the standard diagnosis. Earlier this month, Life Technologies bought Navigenics, a maker of personalized genetic tests. Other instrument makers pushing into diagnostics include Thermo Fisher Scientific and Agilent.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X